107 related articles for article (PubMed ID: 17699730)
1. 213Bi-induced death of HSC45-M2 gastric cancer cells is characterized by G2 arrest and up-regulation of genes known to prevent apoptosis but induce necrosis and mitotic catastrophe.
Seidl C; Port M; Gilbertz KP; Morgenstern A; Bruchertseifer F; Schwaiger M; Röper B; Senekowitsch-Schmidtke R; Abend M
Mol Cancer Ther; 2007 Aug; 6(8):2346-59. PubMed ID: 17699730
[TBL] [Abstract][Full Text] [Related]
2. Differential gene expression triggered by highly cytotoxic alpha-emitter-immunoconjugates in gastric cancer cells.
Seidl C; Port M; Apostolidis C; Bruchertseifer F; Schwaiger M; Senekowitsch-Schmidtke R; Abend M
Invest New Drugs; 2010 Feb; 28(1):49-60. PubMed ID: 19139817
[TBL] [Abstract][Full Text] [Related]
3. Cell death triggered by alpha-emitting 213Bi-immunoconjugates in HSC45-M2 gastric cancer cells is different from apoptotic cell death.
Seidl C; Schröck H; Seidenschwang S; Beck R; Schmid E; Abend M; Becker KF; Apostolidis C; Nikula TK; Kremmer E; Schwaiger M; Senekowitsch-Schmidtke R
Eur J Nucl Med Mol Imaging; 2005 Mar; 32(3):274-85. PubMed ID: 15791436
[TBL] [Abstract][Full Text] [Related]
4. Locoregional alpha-radioimmunotherapy of intraperitoneal tumor cell dissemination using a tumor-specific monoclonal antibody.
Huber R; Seidl C; Schmid E; Seidenschwang S; Becker KF; Schuhmacher C; Apostolidis C; Nikula T; Kremmer E; Schwaiger M; Senekowitsch-Schmidtke R
Clin Cancer Res; 2003 Sep; 9(10 Pt 2):3922S-8S. PubMed ID: 14506190
[TBL] [Abstract][Full Text] [Related]
5. 213Bi-radioimmunotherapy defeats early-stage disseminated gastric cancer in nude mice.
Beck R; Seidl C; Pfost B; Morgenstern A; Bruchertseifer F; Baum H; Schwaiger M; Senekowitsch-Schmidtke R
Cancer Sci; 2007 Aug; 98(8):1215-22. PubMed ID: 17561973
[TBL] [Abstract][Full Text] [Related]
6. 177Lu-immunotherapy of experimental peritoneal carcinomatosis shows comparable effectiveness to 213Bi-immunotherapy, but causes toxicity not observed with 213Bi.
Seidl C; Zöckler C; Beck R; Quintanilla-Martinez L; Bruchertseifer F; Senekowitsch-Schmidtke R
Eur J Nucl Med Mol Imaging; 2011 Feb; 38(2):312-22. PubMed ID: 21072513
[TBL] [Abstract][Full Text] [Related]
7. Fractionated locoregional low-dose radioimmunotherapy improves survival in a mouse model of diffuse-type gastric cancer using a 213Bi-conjugated monoclonal antibody.
Bloechl S; Beck R; Seidl C; Morgenstern A; Schwaiger M; Senekowitsch-Schmidtke R
Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7070s-7074s. PubMed ID: 16203804
[TBL] [Abstract][Full Text] [Related]
8. α-Radioimmunotherapy with ²¹³Bi-anti-CD38 immunoconjugates is effective in a mouse model of human multiple myeloma.
Teiluf K; Seidl C; Blechert B; Gaertner FC; Gilbertz KP; Fernandez V; Bassermann F; Endell J; Boxhammer R; Leclair S; Vallon M; Aichler M; Feuchtinger A; Bruchertseifer F; Morgenstern A; Essler M
Oncotarget; 2015 Mar; 6(7):4692-703. PubMed ID: 25576914
[TBL] [Abstract][Full Text] [Related]
9. Non-invasive visualisation of the development of peritoneal carcinomatosis and tumour regression after 213Bi-radioimmunotherapy using bioluminescence imaging.
Buchhorn HM; Seidl C; Beck R; Saur D; Apostolidis C; Morgenstern A; Schwaiger M; Senekowitsch-Schmidtke R
Eur J Nucl Med Mol Imaging; 2007 Jun; 34(6):841-9. PubMed ID: 17206415
[TBL] [Abstract][Full Text] [Related]
10. ²¹³Bi-anti-EGFR radioimmunoconjugates and X-ray irradiation trigger different cell death pathways in squamous cell carcinoma cells.
Pickhard A; Piontek G; Seidl C; Kopping S; Blechert B; Mißlbeck M; Brockhoff G; Bruchertseifer F; Morgenstern A; Essler M
Nucl Med Biol; 2014 Jan; 41(1):68-76. PubMed ID: 24210808
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the radiotoxicity of two alpha-particle-emitting immunoconjugates, terbium-149 and bismuth-213, directed against a tumor-specific, exon 9 deleted (d9) E-cadherin adhesion protein.
Miederer M; Seidl C; Beyer GJ; Charlton DE; Vranjes-Duric S; Comor JJ; Huber R; Nikula T; Apostolidis C; Schuhmacher C; Becker KF; Senekowitsch-Schmidtke R
Radiat Res; 2003 May; 159(5):612-20. PubMed ID: 12710872
[TBL] [Abstract][Full Text] [Related]
12. Highly specific tumor binding of a 213Bi-labeled monoclonal antibody against mutant E-cadherin suggests its usefulness for locoregional alpha-radioimmunotherapy of diffuse-type gastric cancer.
Senekowitsch-Schmidtke R; Schuhmacher C; Becker KF; Nikula TK; Seidl C; Becker I; Miederer M; Apostolidis C; Adam C; Huber R; Kremmer E; Fischer K; Schwaiger M
Cancer Res; 2001 Apr; 61(7):2804-8. PubMed ID: 11306447
[TBL] [Abstract][Full Text] [Related]
13. Response of LNCaP spheroids after treatment with an alpha-particle emitter (213Bi)-labeled anti-prostate-specific membrane antigen antibody (J591).
Ballangrud AM; Yang WH; Charlton DE; McDevitt MR; Hamacher KA; Panageas KS; Ma D; Bander NH; Scheinberg DA; Sgouros G
Cancer Res; 2001 Mar; 61(5):2008-14. PubMed ID: 11280760
[TBL] [Abstract][Full Text] [Related]
14. Gene expression profiling upon (212) Pb-TCMC-trastuzumab treatment in the LS-174T i.p. xenograft model.
Yong KJ; Milenic DE; Baidoo KE; Kim YS; Brechbiel MW
Cancer Med; 2013 Oct; 2(5):646-53. PubMed ID: 24403230
[TBL] [Abstract][Full Text] [Related]
15. Targeted alpha-therapy using [Bi-213]anti-CD20 as novel treatment option for radio- and chemoresistant non-Hodgkin lymphoma cells.
Roscher M; Hormann I; Leib O; Marx S; Moreno J; Miltner E; Friesen C
Oncotarget; 2013 Feb; 4(2):218-30. PubMed ID: 23474846
[TBL] [Abstract][Full Text] [Related]
16. Anti-CD33-antibodies labelled with the alpha-emitter Bismuth-213 kill CD33-positive acute myeloid leukaemia cells specifically by activation of caspases and break radio- and chemoresistance by inhibition of the anti-apoptotic proteins X-linked inhibitor of apoptosis protein and B-cell lymphoma-extra large.
Friesen C; Roscher M; Hormann I; Leib O; Marx S; Moreno J; Miltner E
Eur J Cancer; 2013 Jul; 49(11):2542-54. PubMed ID: 23684782
[TBL] [Abstract][Full Text] [Related]
17. Claudin 1 mediates tumor necrosis factor alpha-induced cell migration in human gastric cancer cells.
Shiozaki A; Shimizu H; Ichikawa D; Konishi H; Komatsu S; Kubota T; Fujiwara H; Okamoto K; Iitaka D; Nakashima S; Nako Y; Liu M; Otsuji E
World J Gastroenterol; 2014 Dec; 20(47):17863-76. PubMed ID: 25548484
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the biologic effects of MA5 and B-B4 monoclonal antibody labeled with iodine-131 and bismuth-213 on multiple myeloma.
Supiot S; Faivre-Chauvet A; Couturier O; Heymann MF; Robillard N; Kraeber-Bodéré F; Morandeau L; Mahé MA; Chérel M
Cancer; 2002 Feb; 94(4 Suppl):1202-9. PubMed ID: 11877746
[TBL] [Abstract][Full Text] [Related]
19. An alpha-particle emitting antibody ([213Bi]J591) for radioimmunotherapy of prostate cancer.
McDevitt MR; Barendswaard E; Ma D; Lai L; Curcio MJ; Sgouros G; Ballangrud AM; Yang WH; Finn RD; Pellegrini V; Geerlings MW; Lee M; Brechbiel MW; Bander NH; Cordon-Cardo C; Scheinberg DA
Cancer Res; 2000 Nov; 60(21):6095-100. PubMed ID: 11085533
[TBL] [Abstract][Full Text] [Related]
20. Arsenic trioxide induces apoptosis and G2/M phase arrest by inducing Cbl to inhibit PI3K/Akt signaling and thereby regulate p53 activation.
Li Y; Qu X; Qu J; Zhang Y; Liu J; Teng Y; Hu X; Hou K; Liu Y
Cancer Lett; 2009 Nov; 284(2):208-15. PubMed ID: 19457607
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
